-+ 0.00%
-+ 0.00%
-+ 0.00%

NERVGEN RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR NVG-291 IN CHRONIC SPINAL CORD INJURY

路透·11/12/2026 12:15:00

请登录查看新闻详情